Summary
Signal counts
Assets tracked: 2
Watchlist assets: 1
Registry stop assets: 0
Sponsor overview
Shanghai Junshi Bioscience Co., .
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT06885385 | https://clinicaltrials.gov/study/NCT06924606
Assets
Linked programs
- JS207: Watchlist Signal (2/5)
- JS207 injection +docetaxel: Low Signal (0/5)